Taher Muhammad, Susanti Deny, Haris Muhammad Salahuddin, Rushdan Aina Atiqah, Widodo Riyanto Teguh, Syukri Yandi, Khotib Junaidi
Department of Pharmaceutical Technology, Kulliyyah of Pharmacy, International Islamic University Malaysia, 25200, Kuantan, Pahang, Malaysia.
Pharmaceutics and Translational Research Group, Kulliyyah of Pharmacy, International Islamic University Malaysia, 25200, Kuantan, Pahang, Malaysia.
Heliyon. 2023 Feb 17;9(3):e13823. doi: 10.1016/j.heliyon.2023.e13823. eCollection 2023 Mar.
Cancer is a second leading disease-causing death worldwide that will continuously grow as much as 70% in the next 20 years. Chemotherapy is still becoming a choice for cancer treatment despite its severity of side effects and low success rate due to ineffective delivery of the chemodrugs. Since it was introduced in 1960, significant progress has been achieved in the use of liposomes in drug delivery. The study aims to review relevant literatures on role of PEGylated liposome in enhancing cytotoxic activity of several agents. A systematic literature on the use of PEGylated liposomes in anticancer research via Scopus, Google scholar and PubMed databases was conducted for studies published from 2000 to 2022. A total of 15 articles were selected and reviewed from 312 articles identified covering a variety of anticancer treatments by using PEGylated liposomes. PEGylated liposome which is purposed to achieve steric equilibrium is one of enhanced strategies to deliver anticancer drugs. It has been shown that some improvement of delivery and protection form a harsh gastric environment of several anticancer drugs when they are formulated in a PEGylated liposome. One of the successful drugs that has been clinically used is Doxil®, followed by some other drugs in the pipeline Various drugs (compounds) had been used to enhance the efficacy of PEGylated liposomes for targeted cancer cells and in vivo. In conclusion, PEGylated liposomes enhance drug activities and have great potential to become efficient anticancer delivery to follow Doxil® in the clinical setting.
癌症是全球第二大致死疾病，在未来20年将持续增长多达70%。尽管化疗存在副作用严重且由于化疗药物递送无效导致成功率低的问题，但它仍是癌症治疗的一种选择。自1960年引入以来，脂质体在药物递送方面已取得显著进展。本研究旨在综述有关聚乙二醇化脂质体在增强多种药物细胞毒性活性方面作用的相关文献。通过Scopus、谷歌学术和PubMed数据库对2000年至2022年发表的关于聚乙二醇化脂质体在抗癌研究中的应用进行了系统文献检索。从312篇经识别的文章中筛选并综述了15篇文章，这些文章涵盖了使用聚乙二醇化脂质体进行的各种抗癌治疗。旨在实现空间平衡的聚乙二醇化脂质体是递送抗癌药物的增强策略之一。已表明，一些抗癌药物在制成聚乙二醇化脂质体时，其递送和对恶劣胃部环境的保护有所改善。临床上已使用的一种成功药物是多柔比星脂质体（Doxil®），随后还有其他一些正在研发的药物。各种药物（化合物）已被用于增强聚乙二醇化脂质体对靶向癌细胞的疗效以及在体内的疗效。总之，聚乙二醇化脂质体增强了药物活性，在临床环境中极有可能成为继多柔比星脂质体（Doxil®）之后有效的抗癌递送载体。
